AMP Commends SACGHS On Their DNA Patent Report

Main Category: Genetics
Also Included In: Litigation / Medical Malpractice;  Public Health
Article Date: 16 Oct 2009 - 0:00 PDT

email to a friend   printer friendly   opinions  

The Association for Molecular Pathology (AMP) provided comments at the Secretary's Advisory Committee on Genetics, Health and Society (SACGHS) meeting on October 8. AMP opposes the patenting of all naturally occurring genetic material and has signed on as a lead plaintiff in the ACLU case challenging Myriad Genetics' patents on the BRCA 1 and BRCA 2 genes. AMP thanked SACGHS for studying how both patents and restrictive licensing limit patient access and potentially reduce the quality of tests.

The Committee met to review their final draft report on gene patents and licensing practices, and recommended that the administration promote exemptions from liability for infringing on patent claims on genes for anyone making, using, ordering, offering for sale, or selling a test developed under the patent for patient care purposes or in the pursuit of research. They also called for enhanced transparency in licensing activities, public access to information about licensing actions and Federal adoption of efforts to promote broad licensing practices. AMP views this report as a call to action for policymakers to protect all patients from restricting patents and licensing practices.

AMP commends the SACGHS for taking a strong stance against business practices that harm patients, restrict innovation and reduce access to life saving tests. AMP President Dr. Jan Nowak commented, "This report is a milestone in our efforts to improve access to genetic tests. The threat of enforcement from a patent holder and the ensuing litigation costs has created a chilling effect on clinical laboratories making us reluctant to develop new tests that could directly benefit patients."

The task force drafting the report represented the full spectrum of stakeholders and completed a very transparent process with unlimited opportunities for public comment. The final report is authoritative and articulate, and provides a balanced assessment of the consequences of DNA patents. Dr. Nowak further complimented the task force, "The final report represents years of discourse, analysis of expert testimony and data, and the completion of a strong consensus building process. I'm proud of the task force and feel confident that if implemented, this report will benefit patients throughout the country."

AMP congratulates the SACGHS on the publication of their report and encourages Secretary Sebelius to work quickly to adopt and implement their recommendations to protect all Americans from the harms of DNA patents.

AMP's gene patent position statement can be found at http://www.amp.org

Source:
Mary Steele Williams
Association for Molecular Pathology

• Additional
• References
• Citations